RT Journal Article
SR Electronic
T1 May we overcome the current serious limitations for distributing reconstituted mRNA vaccines?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.09.21253129
DO 10.1101/2021.03.09.21253129
A1 Grau, Santiago
A1 Ferrández, Olivia
A1 Martín-García, Elena
A1 Maldonado, Rafael
YR 2021
UL http://medrxiv.org/content/early/2021/03/12/2021.03.09.21253129.abstract
AB There is an urgent need to ameliorate the transport of the reconstituted vaccines to the vaccination sites to improve the COVID-19 vaccination campaigns. The maintenance of the integrity of the mRNA of the different COVID-19 reconstituted vaccines after continuous movement at room temperature during at least three hours ensures the safety of a ground transportation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was recieved.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not aplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available.